What Do FSH and Oestradiol Blood Test Results Mean?

If you have received an FSH or oestradiol result, the first instinct is often to search for a “normal menopause range”. The difficulty is that these hormones are dynamic. Their levels change with the menstrual cycle, during perimenopause and in response to hormonal medicines, so a number that looks high or low is not meaningful without context.

For most otherwise healthy people aged 45 or over with typical menopause symptoms, UK guidance does not recommend routine hormone testing to diagnose menopause. But when testing has been requested for a valid clinical reason, understanding what the result can - and cannot - tell you can make the follow-up conversation much clearer.

FSH stands for follicle-stimulating hormone. It is made by the pituitary gland in the brain and acts as a signal to the ovaries. During the reproductive years, FSH helps stimulate ovarian follicles as part of the menstrual cycle.

As ovarian activity declines, the brain may release more FSH in an attempt to stimulate the ovaries. This is why FSH often becomes higher around menopause. However, the change is not a smooth straight line. During perimenopause, ovarian activity can vary from one cycle to the next, so FSH can be high on one test and lower on another.

That makes FSH useful in selected clinical situations, but much less useful as a one-off “yes or no” menopause test.

Oestradiol (often written as estradiol or E2) is the main form of oestrogen produced by the ovaries during the reproductive years. It plays roles in the menstrual cycle and in tissues including bone, the brain, the cardiovascular system, skin and the vagina and urinary tract.

Oestradiol levels naturally rise and fall across the menstrual cycle. As ovarian activity becomes less predictable during perimenopause, levels can become particularly variable. After menopause, ovarian oestradiol production is generally lower, although the exact blood result still depends on the individual situation and any hormone treatment being used.

A blood test measures the oestradiol present in the sample at that moment. It does not show every rise and fall that happened during the rest of the day, cycle or previous weeks.

Timing matters because FSH and oestradiol are part of a changing hormonal system rather than fixed biomarkers. A result can be influenced by where you are in the menstrual cycle, whether ovulation has occurred, how irregular your cycles have become and whether you are in perimenopause.

Hormonal contraception and HRT can also change the levels being measured or make some results harder to interpret for a particular purpose. Laboratory methods and reference ranges may differ too, which is another reason a result should be read using the range supplied by that laboratory rather than a number copied from the internet.

If a result does not seem to fit your symptoms or clinical history, the useful next step may be to review why the test was requested, when it was taken and whether treatment or cycle timing affected it - rather than assuming the result is simply “wrong”.

A higher FSH result can be consistent with reduced ovarian activity. In the right context, that may support a diagnosis of menopause, early menopause or premature ovarian insufficiency. But the context matters.

During perimenopause, FSH can move up and down considerably. A single high result therefore does not tell you that menopause is complete, and a normal or lower result does not reliably rule out perimenopause.

Age is particularly important. UK guidance uses FSH selectively when menopause is suspected in younger people, where confirming reduced ovarian function can have implications for diagnosis and longer-term care. For most otherwise healthy people aged 45 or over with typical symptoms, menopause is generally identified from the clinical picture rather than from routine FSH testing.

If your FSH result is unexpectedly high, the clinician will consider your age, menstrual history, symptoms, contraception or HRT use and the reason for testing before deciding whether the result needs repeating or further assessment.

A low oestradiol result can be consistent with lower ovarian oestrogen production, including after menopause. However, one low result cannot by itself establish where someone is in the menopause transition.

In perimenopause, oestradiol can be low on one day and considerably higher on another. The result may also be affected by cycle timing and by whether someone is using HRT or another hormonal medicine.

If oestradiol is measured while someone is using transdermal HRT, such as a patch, gel or spray, the result may sometimes provide supporting information about oestrogen exposure or possible absorption. Even then, the number needs to be interpreted with symptoms, dose, formulation, timing and correct treatment use rather than treated as a standalone target.

A low result also does not explain every symptom. Fatigue, low mood, brain fog, sleep disturbance and other midlife symptoms can have several possible causes, so the wider clinical picture still matters.

FSH testing is most useful when it answers a specific diagnostic question. NICE recommends considering FSH to confirm menopause in people aged 40 to 45 who have menopause-associated symptoms and a change in their menstrual cycle, and in people under 40 when menopause is suspected.

It may also be relevant when the menstrual history is difficult to use, although medicines and individual circumstances can affect whether the result will be interpretable. NICE advises against using FSH to identify menopause in people using combined oestrogen-and-progestogen contraception or high-dose progestogen.

Not by themselves. HRT is usually reviewed using symptoms, side effects, bleeding, medical history, treatment use and clinical risk rather than by aiming for one universal hormone number.

FSH is not normally used as a dose target once someone is taking HRT. Oestradiol testing may sometimes be useful when there is a specific question - for example, persistent symptoms despite apparently correct use of transdermal oestrogen, concern about poor absorption, or a more complex treatment situation.

The British Menopause Society notes that there is no recommended systemic oestrogen level for routine HRT use and that a single serum oestradiol result is affected by factors including dose timing and assay method. More recent BMS guidance also highlights that serum oestradiol can sometimes help investigate absorption when distressing symptoms continue, while recognising the uncertainty around a single measurement.

This means an oestradiol result can be supporting evidence, but it should not automatically lead to a dose increase or decrease. For more detail on monitoring treatment, read Blood Tests Before and During HRT: When Are They Useful?

The most useful interpretation is usually the one that answers the original clinical question. A hormone number is not a diagnosis in isolation.